000277750 001__ 277750
000277750 005__ 20241220120853.0
000277750 0247_ $$2doi$$a10.1155/2023/6909414
000277750 0247_ $$2pmid$$apmid:37457920
000277750 0247_ $$2pmc$$apmc:PMC10348860
000277750 0247_ $$2ISSN$$a1687-9589
000277750 0247_ $$2ISSN$$a1687-9597
000277750 0247_ $$2altmetric$$aaltmetric:152311322
000277750 037__ $$aDKFZ-2023-01467
000277750 041__ $$aEnglish
000277750 082__ $$a610
000277750 1001_ $$aTichanek, Filip$$b0
000277750 245__ $$aSurvival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries.
000277750 260__ $$aNew York, NY$$bHindawi$$c2023
000277750 3367_ $$2DRIVER$$aarticle
000277750 3367_ $$2DataCite$$aOutput Types/Journal article
000277750 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690808556_20266
000277750 3367_ $$2BibTeX$$aARTICLE
000277750 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277750 3367_ $$00$$2EndNote$$aJournal Article
000277750 500__ $$a#LA:C020# / 2023 Jul 7;2023:6909414
000277750 520__ $$aFemale cancers cover common breast cancers, relatively common endometrial, ovarian, and cervical cancers and rare vulvar cancer. Survival in these cancers is known to be relatively good compared to all cancers but long-term studies for these cancers are rare, and to fill the gap, here, we generate survival data through 50 years.We applied generalized additive models to data from the NORDCAN database and analyzed 1- and 5-year relative survival for these cancers in Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) over half a century (1971-2020). Conditional 5/1-year survival for patients who survived the 1st year after diagnosis and annual survival changes was also estimated.In 2016-20, 5-year survival was best for breast cancer reaching 92.3% (in SE), followed by endometrial cancer at 86.1% (SE) and cervical cancer at 75.6% (NO). Improvement in 5-year survival over the 50 years was the largest for ovarian cancer (20% units), finally reaching 52.9% (SE). For vulvar cancer, the final survival was between 70 and 73%. The best 5-year survival rate in 2016-20 was recorded for SE in breast, endometrial, and ovarian cancers; NO showed the highest rate for cervical and DK for vulvar cancers. DK had the lowest survival for breast and ovarian cancers, and FI, for the other cancers.The overall survival development appeared to consist of continuous improvements, most likely because of novel treatment and imaging techniques as well as overall organization of patient care. The large survival improvement for ovarian cancer was probably achieved by a surgical focus on tumors spread in the peritoneal cavity. For cervical and vulvar cancers, the high early mortality requires attention and could be helped by raising increasing public awareness of early symptoms in these cancers and developing pathways for fast initiation of treatment.
000277750 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277750 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277750 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000277750 7001_ $$aHemminki, Otto$$b2
000277750 7001_ $$aHemminki, Akseli$$b3
000277750 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000277750 773__ $$0PERI:(DE-600)2495157-2$$a10.1155/2023/6909414$$gVol. 2023, p. 1 - 9$$p1 - 9$$tObstetrics and gynecology international$$v2023$$x1687-9589$$y2023
000277750 8767_ $$8W-2023-00473-b$$92023-09-08$$d2024-12-19$$eAPC$$jZahlung erfolgt
000277750 909CO $$ooai:inrepo02.dkfz.de:277750$$pVDB$$pOpenAPC$$popenCost
000277750 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277750 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000277750 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277750 9141_ $$y2023
000277750 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-06-16T15:52:59Z
000277750 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000277750 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000277750 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:01:12Z
000277750 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:01:12Z
000277750 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:01:12Z
000277750 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bOBSTET GYNECOL INT : 2022$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000277750 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000277750 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000277750 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000277750 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000277750 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000277750 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277750 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000277750 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000277750 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000277750 980__ $$ajournal
000277750 980__ $$aVDB
000277750 980__ $$aI:(DE-He78)B062-20160331
000277750 980__ $$aI:(DE-He78)HD01-20160331
000277750 980__ $$aI:(DE-He78)C020-20160331
000277750 980__ $$aUNRESTRICTED
000277750 980__ $$aAPC